Malaria drug repurposed for lung disease?
NCT ID NCT06872112
First seen Jan 10, 2026 · Last updated May 23, 2026 · Updated 13 times
Summary
This early-stage study tests whether artesunate, a malaria drug, is safe for people with pulmonary arterial hypertension (PAH). Fifteen adults with PAH will take daily oral artesunate for 20 weeks. The main goal is to check for side effects, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION PAH are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.